Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcomeJuan María Roldán‐Romero, Cristina Rodríguez‐Antona, Luis J. Leandro‐García et al.|Modern Pathology|2020Cited by 56
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinomaMaría Santos, Cristina Rodríguez‐Antona, Javier Lanillos et al.|Genetics in Medicine|2021Cited by 22
Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.Dominick Bossé, Toni K. Choueiri, Wanling Xie et al.|Journal of Clinical Oncology|2018Cited by 9
Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.Dominick Bossé, Toni K. Choueiri, Wanling Xie et al.|Journal of Clinical Oncology|2018Cited by 1
First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).Shaan Dudani, Daniel Yick Chin Heng, Jeffrey Graham et al.|Journal of Clinical Oncology|2019Cited by 1